The authors of a new study in the Annals of Internal Medicine believe too many patients are being recommended statin therapy, and contend that current guidelines don’t fully consider the risks of the popular drugs.

Contrary to U.S. guidelines, early action against high BP in patients exhibiting signs of hypertension doesn’t reduce their risk of heart disease later in life, according to a study published in the European Heart Journal Nov. 21.

A new expert consensus document from the American College of Cardiology singled out liraglutide and empagliflozin as the preferred drugs in their classes to reduce cardiovascular risk among patients with type 2 diabetes and atherosclerotic cardiovascular disease.

Smoke-free policies in public places like bars and restaurants were linked to lower systolic blood pressures (SBPs) among participants from the longitudinal CARDIA study, according to new research published in the Journal of the American Heart Association.

An observational study of nearly 35,000 Scandinavian patients with type 2 diabetes (T2D) has found sodium-glucose cotransporter 2 (SGLT2) inhibitors, a class of prescription drugs approved by the FDA to lower blood sugar in adults with T2D, may almost double patients’ risks of lower limb amputation and diabetic ketoacidosis compared to glucagon-like peptide 1 (GLP1) receptor agonists.

A study of two neighboring communities living in the remote Venezuelan rainforest is poking holes in the idea that blood pressure inevitably increases with age.

A third blood pressure drug has been recalled over a carcinogenic impurity, the FDA announced Nov. 8.

VITAL and REDUCE-IT—both highly anticipated trials revolving around the cardiovascular benefits of fish oil products—delivered mixed results at this year’s AHA Scientific Sessions in Chicago, with one trial observing few heart benefits from omega-3s while the other saw a 25 percent reduction in major cardiovascular events with a purified eicosapentaenoic acid product.